A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer.
Denise DragoAnnapaola AndolfoEttore MoscaAlessandro OrroLuigi NoceraVito CucchiaraMatteo BelloneFrancesco MontorsiAlberto BrigantiPublished in: Cancer biology & medicine (2021)
A combination of metabolites and clinical variables can effectively help in identifying PCa patients that might be overlooked by current imaging technologies. Metabolites from EPS-urine should help in defining the diagnostic pathway of PCa, thus improving PCa detection and decreasing the number of unnecessary prostate biopsies.
Keyphrases
- prostate cancer
- radical prostatectomy
- end stage renal disease
- ms ms
- ejection fraction
- newly diagnosed
- benign prostatic hyperplasia
- chronic kidney disease
- high resolution
- prognostic factors
- peritoneal dialysis
- mass spectrometry
- ultrasound guided
- loop mediated isothermal amplification
- patient reported
- sensitive detection